Can-Fite gets Eurasian patent allowance for piclidenoson in Lowe syndrome

Can-Fite BioPharma Ltd. said on November 2, 2026 that the Eurasian Patent Office issued a notification of readiness to grant a patent covering the use of Piclidenoson for treating diseases tied to OCRL deficiency, including Lowe syndrome and Dent disease 2.¹ The grant has not yet been finalized, as the grant remains subject to completion of the required formalities.¹

Lowe syndrome is described as a rare X-linked multisystem genetic disorder caused by mutations in the OCRL gene, resulting in severe renal, neurological, and ocular manifestations.¹ Its renal component involves proximal tubular dysfunction that progresses toward Fanconi syndrome, chronic kidney disease, and eventually kidney failure.¹ The company noted there is currently no approved therapy that targets the disease's underlying mechanism, with management limited to supportive care.¹

The underlying patent application belongs to Fondazione Telethon, described as Can-Fite's research partner.¹ Per their agreement, Can-Fite holds rights to develop, commercialize, and out-license Piclidenoson for Lowe syndrome.¹ The two parties have also signed a collaboration agreement to advance clinical development of Piclidenoson for Lowe syndrome.¹

A related Phase 2 trial is structured as an open-label, single-center study testing oral Piclidenoson dosed twice daily over six months in five genetically confirmed Lowe syndrome patients.¹ Its main goal is measuring improvement in renal uptake of 99mTc-DMSA as an indicator of proximal tubular reabsorption, alongside secondary measures of urinary biomarkers, Fanconi syndrome parameters, and safety.¹

Separately, Piclidenoson is also being tested in a pivotal Phase 3 psoriasis study cleared by both the FDA and the EMA.¹